BLURB

Matter Bio is a longevity biotech on a mission to treat age-related diseases by preserving genome integrity—strengthening DNA repair and clearing cells burdened by excessive damage (e.g., cancer). Inspired by nature’s longest-lived species, we harness superior DNA-stability variants to bolster human cell health and deploy engineered bacteria to seek out and destroy tumors. Our pipeline combines revenue-generating ecNGS sequencing services, a Phase 1 solid-tumor program, and a preclinical DNA-repair platform. Led by veteran CEO Chris Bradley and science pioneers George Church, Jan Vijg, and Claudia Gravekamp, Matter Bio is translating nature’s blueprint for longevity into human therapies

LONG FORM

Matter Bio: Protecting the Genome

Matter Bio is a longevity company committed to treating the diseases of aging by protecting cells from DNA damage and removing cells that have accumulated too much damage (e.g. cancer).

Drawing inspiration from the information theory of aging, we posit that age-related diseases—and possibly aging itself—result from the accumulated loss of DNA integrity due to damage.

Problem

As we age, our genomes accrue damage from both external and internal sources at a roughly linear rate. While cells possess powerful DNA repair mechanisms, these systems are not infallible. Errors can be missed, leading to mutations, structural variations, epigenetic drift, and other forms of information loss. This accumulation triggers a cascade of problems that culminate in age-related diseases.

Solution

Nature's Blueprint for Longevity

Research into extreme longevity across various species reveals a consistent pattern: longer-lived animals exhibit superior genome stability and DNA repair capabilities compared to their shorter-lived counterparts. This not only leads to longer life, but also to drastically reduced incidence of cancer and other diseases of aging.

This phenomenon has been observed across many species such as naked mole rats, rockfish, bowhead whales, Greenland sharks, and even supercentenarian humans.

At Matter, we aim to harness these naturally occurring DNA stability variants and deliver them to human cells to dramatically enhance cellular longevity. When cancer is already present, we delivery an engineered bacteria to find and kill tumor cells, wherever they are.